NRX Pharmaceuticals (NRXP) Return on Capital Employed (2018 - 2026)

NRX Pharmaceuticals (NRXP) has 9 years of Return on Capital Employed data on file, last reported at 134.31% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 7404.0% year-over-year to 134.31% in Q1 2026; TTM through Mar 2026 was 134.31%, a 7404.0% increase from a year earlier, with the FY2025 full-year figure at 80.02%, down 3293.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 134.31%, up from 111.11% in the prior quarter.
• Over the last five years, Return on Capital Employed for NRXP reached as high as 1704.47% in Q2 2023 and fell as low as 1872.9% in Q1 2023.
• Historically, Return on Capital Employed has averaged 101.76% across 5 years, with a median of 107.51% in 2025.
• Across the five-year window, Return on Capital Employed surged 70722 bps in 2023 and plunged 83443 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 455.41% in 2022, then jumped by 155 bps to 251.81% in 2023, then plunged by 59 bps to 103.91% in 2024, then grew by 7 bps to 111.11% in 2025, then advanced by 21 bps to 134.31% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 134.31% in Q1 2026, 111.11% in Q4 2025, and 45.75% in Q3 2025.